Form 4: Perspective Therapeutics Executive Acquires 150,000 Stock Options
SEC Form 4 Filing
Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics, Inc., reports the acquisition of 150,000 stock options.
Summary
- Markus Puhlmann, the Chief Medical Officer of Perspective Therapeutics, Inc. (CATX), filed a Form 4 with the SEC.
- The filing reports a transaction on June 20, 2024, where Puhlmann acquired 150,000 stock options.
- The exercise price of these options is $10.65.
- The options vest over four years, with 1/48th of the shares vesting monthly starting from the grant date.
- The options expire on June 20, 2034.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting an executive's acquisition of stock options. It's a neutral event with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company executives.
Stakeholder Impact
- The granting of stock options aligns the executive's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of earliest transaction: Grant date of stock options. |
| 06/24/2024 | Date of signature on the Form 4 filing. |
| 06/20/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.